Drug intelligence / Profile preview

Physogen

Development stage: Unknown
Lead developer: Neimeth International Pharmaceuticals
Administration: Oral

Overview

**Physogen** is a marketed oral phytomedicine from Neimeth for the symptomatic treatment of common cold infections. Neimeth identifies Physogen as one of its research-and-development successes and describes it as already marketed. Publicly available sources reviewed do not disclose its precise active ingredients, dosage form, pharmacological targets, or molecular mechanism of action. ([neimethplc.com.ng](https://www.neimethplc.com.ng/research-and-development/))

Brand names: Physogen

Beyond the preview

Go deeper on Physogen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Physogen.

Explore the full profile